

Checklist for Prescribers:

Initiation of ^{Pr}MINT-EMTRICITABINE/TENOFOVIR for Pre-exposure Prophylaxis (PrEP) in adults at high risk of HIV-1 infection

Γ		\neg
 	Individual Label	
L		

Instructions:

Complete checklist at each visit and file in individual's medical record.

I have completed the following prior to prescribing MINT-EMTRICITABINE/TENOFOVIR for a pre-exposure prophylaxis (PrEP) indication for the individual who is about to start or is taking MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication:

LAB LESIS / EVALUATION		COUR	COUNSELING / FOLLOW-UP		
	Completed high risk evaluation of uninfected individual	_	iscussed known safety risks with use of MINT- MTRICITABINE/TENOFOVIR for a PrEP indication		
•	Confirmed a negative HIV-1 test immediately prior to initiating MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposure is suspected, delay starting PrEP for at least 1 month	ev	Counseled on the importance of scheduled follow-up every 2 to 3 months, including regular HIV-1 screening tests (at least every 3 months), while taking MINT-		
			MTRICITABINE/TENOFOVIR for PrEP to reconfirm HIV- negative status		
	and reconfirm HIV-1 status or use a test approved by Health Canada as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. (Note: MINT-EMTRICITABINE/ TENOFOVIR for a PrEP indication is contraindicated in individuals with	EN se	iscussed the importance of discontinuing MINT- MTRICITABINE/TENOFOVIR for a PrEP indication if Proconversion has occurred, to reduce the evelopment of resistant HIV-1 variants		
	unknown HIV-1 status or who are HIV-1 positive) Performed HBV screening test		ounseled on the importance of adherence to daily osing schedule		
	Confirmed estimated creatinine clearance (CrCl) ≥ 60 mL/min prior to initiation and periodically during treatment. In patients at risk for renal dysfunction, assess estimated CrCl, serum phosphorus, urine glucose and urine protein before initiation of MINT-	 Pr	counseled that MINT-EMTRICITABINE/TENOFOVIR for a EP indication should be used only as part of a comprehensive prevention strategy		
			ducated on practicing safer sex consistently and using condoms correctly		
	EMTRICITABINE/TENOFOVIR and periodically while MINT-EMTRICITABINE/TENOFOVIR is being used. If a decrease in estimated CrCl is observed in uninfected individuals while using MINT-EMTRICITABINE/	th	iscussed the importance of the individual knowing eir HIV-1 status and, if possible, that of their artner(s)		
	TENOFOVIR for PrEP, evaluate potential causes and reassess potential risks and benefits of continued use	se	scussed the importance of and performed screening for exually transmitted infections (STIs), such as syphilis and		
	Confirmed that the uninfected individual at high risk is not taking other HIV-1 medications or HBV	_	onorrhea, that can facilitate HIV-1 transmission ffered HBV vaccination as appropriate		
	medications Evaluated risk/benefit for women who may be pregnant or may want to become pregnant	EN	rovided education on where information about MINT- MTRICITABINE/TENOFOVIR for a PrEP indication can e accessed		
		Di	iscussed potential adverse reactions		
		-U	eviewed the MINT-EMTRICITABINE/TENOFOVIR ninfected Individual Safety Brochure with the ninfected individual at high risk		

MINT-EMTRICITABINE/TENOFOVIR is indicated in combination with safer sex practices for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. Consult the product monograph at www.mintpharmaceuticals.com for contraindication, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-877-398-9696.